TBPH insider filings

Theravance Biopharma, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-16. Screen TBPH transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 18 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS3—3 legs · 13,314 sh · $226,7934
Smaldone Alsup Laurie — Director1——12
MITCHELL DEAN J — Director1——11
O'Connor Donal — Director1——11
PAKIANATHAN DEEPIKA — Director1——9
GRAY SUSANNAH — Director1——7
Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director2——7
Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARY2——4
Miller Aine — SVP, DEV & HEAD OF IRE OFFICE2——4
Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICER2——4

+2 more insiders in the window, not shown — every filing appears in the table below.

Recent insider filings — Theravance Biopharma, Inc.

FiledFormInsiderReported transactionsSource
2026-11-164Samaha Eli — 10% ownerOther (J): 9,167,489 @ $17EDGAR
2026-09-284Weiss Asset Management LP
WEISS ANDREW M
WAM GP LLC
Other (J): 7,457,060 @ $17EDGAR
2026-09-244O'Connor Donal — DirectorDisposition to issuer (D): 74,204 · Disposition to issuer (D): 6,009 · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · +5 moreEDGAR
2026-09-244PAKIANATHAN DEEPIKA — DirectorDisposition to issuer (D): 58,065 · Disposition to issuer (D): 6,009 · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 28,000 (derivative) · Disposition to issuer (D): 22,044 (derivative) · +3 moreEDGAR
2026-09-244GRAY SUSANNAH — DirectorDisposition to issuer (D): 42,137 · Disposition to issuer (D): 6,009 · Disposition to issuer (D): 32,666 (derivative) · Disposition to issuer (D): 22,044 (derivative) · Disposition to issuer (D): 23,576 (derivative) · Disposition to issuer (D): 24,258 (derivative) · +1 moreEDGAR
2026-09-244MITCHELL DEAN J — DirectorDisposition to issuer (D): 91,204 · Disposition to issuer (D): 6,009 · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · +5 moreEDGAR
2026-09-244Smaldone Alsup Laurie — DirectorDisposition to issuer (D): 74,980 · Disposition to issuer (D): 6,009 · Disposition to issuer (D): 13,500 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · +6 moreEDGAR
2026-09-244Miller Aine — SVP, DEV & HEAD OF IRE OFFICEDisposition to issuer (D): 93,108 · Disposition to issuer (D): 96,718 · Disposition to issuer (D): 37,500 (derivative)EDGAR
2026-09-244Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICERDisposition to issuer (D): 204,966 · Disposition to issuer (D): 108,436 · Disposition to issuer (D): 23,439EDGAR
2026-09-244Winningham Rick E — CHIEF EXECUTIVE OFFICER, DirectorDisposition to issuer (D): 1,382,272 · Disposition to issuer (D): 151,875 · Disposition to issuer (D): 76,875 · Disposition to issuer (D): 23,400 · Disposition to issuer (D): 92,567 · Disposition to issuer (D): 515,000 (derivative)EDGAR
2026-09-244Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSDisposition to issuer (D): 124,414 · Disposition to issuer (D): 89,062 · Disposition to issuer (D): 150,000 (derivative)EDGAR
2026-09-244Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARYDisposition to issuer (D): 223,917 · Disposition to issuer (D): 107,812 · Disposition to issuer (D): 23,439EDGAR
2026-09-174Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSSale (S): 3,329 @ $17.03 · Sale (S): 3,328 @ $17.03 · Sale (S): 6,657 @ $17.03EDGAR
2026-08-244Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICERTax withholding (F): 8,112 @ $16.95EDGAR
2026-08-244Winningham Rick E — CHIEF EXECUTIVE OFFICER, DirectorTax withholding (F): 20,034 @ $16.95EDGAR
2026-08-244Miller Aine — SVP, DEV & HEAD OF IRE OFFICETax withholding (F): 6,258 @ $16.95EDGAR
2026-08-244Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSTax withholding (F): 5,667 @ $16.95EDGAR
2026-08-244Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARYTax withholding (F): 7,952 @ $16.95EDGAR
2026-07-084Samaha Eli — 10% ownerSale (S): 1,400 @ $17.04 · Sale (S): 5,564 @ $17.17EDGAR
2026-07-014Samaha Eli — 10% ownerSale (S): 273,871 @ $17.23 · Sale (S): 25,027 @ $17.13 · Sale (S): 37,799 @ $17.00EDGAR
2026-06-234Miller Aine — SVP, DEV & HEAD OF IRE OFFICEGrant/award (A): 18,750 @ $0EDGAR
2026-06-174Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSSale (S): 3,329 @ $16.39 · Sale (S): 3,328 @ $16.38 · Sale (S): 6,657 @ $16.39EDGAR
2026-06-164GRAY SUSANNAH — DirectorGrant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0EDGAR
2026-06-164O'Connor Donal — DirectorGrant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0EDGAR
2026-06-164Smaldone Alsup Laurie — DirectorGrant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0EDGAR
2026-06-164PAKIANATHAN DEEPIKA — DirectorGrant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0EDGAR
2026-06-164MITCHELL DEAN J — DirectorGrant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0EDGAR
2026-05-224Miller Aine — SVP, DEV & HEAD OF IRE OFFICETax withholding (F): 6,827 @ $16.55EDGAR
2026-05-224Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARYTax withholding (F): 8,829 @ $16.55EDGAR
2026-05-224Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICERTax withholding (F): 8,670 @ $16.55EDGAR
2026-05-224Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSTax withholding (F): 5,678 @ $16.55EDGAR
2026-05-224Winningham Rick E — CHIEF EXECUTIVE OFFICER, DirectorTax withholding (F): 20,038 @ $16.55EDGAR
2026-04-034Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARYGrant/award (A): 37,500 @ $0EDGAR
2026-04-034Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICERGrant/award (A): 37,500 @ $0EDGAR
2026-04-034Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSGrant/award (A): 18,750 @ $0EDGAR
2026-04-034Winningham Rick E — CHIEF EXECUTIVE OFFICER, DirectorGrant/award (A): 75,000 @ $0EDGAR
2026-03-184Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSSale (S): 7,767 @ $13.92 · Sale (S): 15,534 @ $14 · Sale (S): 7,766 @ $13.92EDGAR
2026-02-244Miller Aine — SVP, DEV & HEAD OF IRE OFFICETax withholding (F): 16,851 @ $19.66EDGAR
2026-02-244Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARYTax withholding (F): 20,833 @ $19.66EDGAR
2026-02-244Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICERTax withholding (F): 20,672 @ $19.66EDGAR
2026-02-244Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSTax withholding (F): 13,929 @ $19.66EDGAR
2026-02-244Winningham Rick E — CHIEF EXECUTIVE OFFICER, DirectorTax withholding (F): 74,975 @ $19.66EDGAR
2025-12-054Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSSale (S): 7,767 @ $18.75 · Sale (S): 7,766 @ $18.75 · Sale (S): 15,534 @ $18.75EDGAR
2025-12-014BROSHY ERAN — DirectorSale (S): 14,000 @ $20 · Sale (S): 15,501 @ $20 · Option exercise (M): 14,000 (derivative) @ $10.15EDGAR
2025-11-244Miller Aine — SVP, DEV & HEAD OF IRE OFFICETax withholding (F): 6,989 @ $17.90EDGAR
2025-11-244Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARYTax withholding (F): 19,024 @ $17.90EDGAR
2025-11-244Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICERTax withholding (F): 18,627 @ $17.90EDGAR
2025-11-244Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRSTax withholding (F): 9,060 @ $17.90EDGAR
2025-11-214Winningham Rick E — CHIEF EXECUTIVE OFFICER, DirectorGift (G): 9,900 @ $0 · Gift (G): 9,900 @ $0 · Tax withholding (F): 56,817 @ $17.90EDGAR
2025-11-144/ABROSHY ERAN — DirectorSale (S): 15,500 @ $18.50 · Sale (S): 15,500 @ $17 · Sale (S): 14,000 @ $18.50 · Option exercise (M): 14,000 (derivative) @ $10.15EDGAR

Recent 8-K events — Theravance Biopharma, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-09-238-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-188-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-09-108-K8.01 — Other EventsEDGAR
2026-08-258-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-298-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-238-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-06-128-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-308-K8.01 — Other EventsEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TBPH returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs